In her new book, “Outliving Your Ovaries,” Endocrinologist Dr. Marina Johnson reveals compelling research that compares the risks and benefits of Hormone Replacement Therapy (HRT) to statins and other commonly used drugs.
The FDA considers the risks from statins “acceptable” while they give HRT a “black box” warning not required of statins and other drugs with a similar risk of breast cancer.
Thirty randomized controlled trials of women taking pharmaceutical HRT ( have shown a 40% reduction in mortality yet statins have not been shown to reduce mortality in women. Dr. Johnson emphasizes the point is not to advocate or criticize the use of one drug or another but to use some common sense and put the risks and benefits in clinical perspective. The risks of breast cancer from statins or HRT are rare (less than 1 event per 1000 women) and should be considered in light of potential benefits.
These studies appeared in the Cleveland Clinic Journal of Medicine and the Journal of the North American Menopause Society.
Hodis, HN, “Assessing benefits and risks of hormone therapy in 2008: new evidence, especially with regard to the heart,” Cleveland Clinic Journal of Medicine, vol 75(4) (2008): pp S3-S12.
Excerpt From Dr. Johnson’s book
“In a compelling 2008 review of multiple studies, Dr. Howard N. Hodis, a cardiologist in the preventive cardiology unit at USC School of Medicine, compared the risks and benefits of hormone replacement therapy for preventing heart disease with that of drugs like “statins,” cholesterol-lowering drugs, commonly used for heart disease.
A meta analysis of 30 randomized controlled trials comparing women taking HRT to those on no HRT showed a 40% reduced mortality in women who started HRT younger than 60 or within 10 years of menopause. Contrast this to cholesterol-lowering drugs, like statins, which have not been shown to reduce mortality in women.”
This is but one example of the ground-breaking research Dr. Johnson has included in her new book, “Outliving Your Ovaries”
Dr. Johnson is a UCLA/USC trained, board-certified endocrinologist and a former assistant editor of AHFS-Drug Information, a comprehensive drug reference book, analyzes the latest HRT research in clear, easy-to-understand terms a woman can understand. Dr. Johnson has no financial conflicts of interest or ties to any pharmaceutical company. Her only objective is determining the most effective, safest therapy for patients. Her book gives a woman a guidebook so she can better work with their own physician to determine the best decisions for her individual case.